HY2CARE BV

Their core work

HY2CARE BV is a Dutch biotech SME based in Geleen, specializing in injectable hydrogel biomaterials for cartilage repair and regeneration. Their proprietary technology centers on formulating hydrogels that can be delivered by injection into damaged cartilage tissue, avoiding more invasive surgical procedures. They also hold expertise in advanced pharmaceutical formulation science, as evidenced by their participation in a cross-sectoral project on next-generation drug delivery systems. Their location in Geleen — historically a hub for Dutch chemical and life science industry — reflects a product-oriented, application-driven company rather than an academic spinout.

What they specialise in

How they've shifted over time

Both H2020 projects launched in the same year (2016), making it impossible to trace a meaningful temporal evolution from the project timeline alone. What can be inferred is a dual-track focus from the outset: a proprietary product track (injectable hydrogels for orthopedic use, run as coordinator) and a knowledge-building track (pharmaceutical formulations, joined as an MSCA-RISE partner to access academic expertise and researcher exchange). Whether the company has since advanced their hydrogel product toward clinical trials or pivoted into broader drug delivery markets cannot be determined from the available H2020 data.

Their combination of a self-led product project and an MSCA knowledge-exchange project suggests a company building toward clinical or commercial translation of biomaterial technology, likely seeking academic and industrial partners who can support regulatory or scale-up stages.

How they like to work

HY2CARE has both led and joined projects — coordinating their own SME-1 grant while also participating in an MSCA-RISE exchange network, which is unusual for a company with only two projects and suggests deliberate strategic use of EU instruments. Their consortia are very small (3 partners across 3 countries), consistent with a focused SME that values targeted collaboration over broad networks. Working with them likely means engaging directly with the founders or core technical team on a clearly defined, application-specific brief.

HY2CARE has worked with just 3 unique partners across 3 countries, reflecting the compact structure typical of SME-phase biotech companies. Their network is small but deliberately international, spanning at least one academic and one industry partner through MSCA-RISE.

What sets them apart

HY2CARE appears to be one of the few Dutch SMEs in H2020 targeting the specific intersection of injectable biomaterials and cartilage repair — a niche with clear clinical demand but few dedicated product companies at SME scale. Their willingness to both coordinate EU projects and join academic exchange networks suggests a technically credible team capable of bridging lab-stage biomaterials research and product development. For consortium builders in regenerative medicine or advanced drug delivery, they offer a rare combination: a commercializing SME that also engages with open research environments.

Highlights from their portfolio

• Hy2Care
  This is HY2CARE's own named technology project — coordinated under the SME Instrument Phase 1 — making it the clearest signal of their core commercial product and go-to-market intent.
• FutForm
  An MSCA-RISE project running four years (2016–2020) on future pharmaceutical formulations, demonstrating the company's ability to embed itself in academic-industrial research exchange networks beyond their immediate product focus.